Dynavax Technologies Corp (NASDAQ:DVAX)

CAPS Rating: 3 out of 5

A biopharmaceutical company that discovers and develops Toll-like Receptor 9 and agonist-based products to treat and prevent infectious diseases, allergies, cancer and chronic inflammatory.

Recs

0
Player Avatar Biotoday (31.51) Submitted: 10/7/2010 3:31:55 PM : Outperform Start Price: $1.86 DVAX Score: +81.66

They keep attracting money.

Featured Broker Partners


Advertisement